Abstract Overexpression of c-Kit has recently been shown to ameliorate beta cell function by increasing the beta cell mass and insulin secretion, thus counteracting the deleterious effects of a high-fat diet on glucose homeostasis. The c-Kit-dependent effects are due to enhanced Akt activity that phosphorylates and inhibits glycogen synthase kinase 3β (GSK3β), thereby increasing the expression of numerous genes that promote insulin production and cell proliferation. Regulating the c-Kit/Akt/GSK3β pathway may provide novel means for improving beta cell function in type 2 diabetes. The importance of PDGF for beta cells has been known for many years and early studies indicated that PDGF stimulates beta cell replication [4] , that this effect is promoted by overexpression of PDGF receptors [5] and that PDGF receptors are expressed in pancreatic epithelial cells during embryonic development [6] . Recently, an age-dependent decrease in PDGF receptor expression was described that diminished the proliferative potential of beta cells, and beta cell-specific inactivation of the gene encoding PDGF receptor α (Pdgfra) aggravated susceptibility to the beta cell toxin streptozotocin [7] . These results implicate PDGF receptors as potential targets for additional treatment regimens for diabetes. This could involve the administration of PDGF ligands and/or increased expression of PDGF receptors in beta cells.
receptors are important for vascular mural cells, glial cells in the central nervous system and the formation of lung alveoli, intestinal villi and hair follicles [2] . These tyrosine kinase receptors have the ability to stimulate cell proliferation, increase survival and cause cellular differentiation and migration by signalling through the extracellular-signal regulated kinase (ERK) and phosphoinositide-3-kinase (PI3K) pathways. Several oncogenic mutants of these receptors and/or their corresponding ligands have been characterised.
The group of Dr Rennian Wang, at the University of Western Ontario in Canada, has for several years systematically pursued a line of research investigating the role of c-Kit in beta cells. These studies have culminated in the exciting story of the c-Kit-dependent rescue of beta cell failure, which is published in this issue of Diabetologia [3] .
The importance of PDGF for beta cells has been known for many years and early studies indicated that PDGF stimulates beta cell replication [4] , that this effect is promoted by overexpression of PDGF receptors [5] and that PDGF receptors are expressed in pancreatic epithelial cells during embryonic development [6] . Recently, an age-dependent decrease in PDGF receptor expression was described that diminished the proliferative potential of beta cells, and beta cell-specific inactivation of the gene encoding PDGF receptor α (Pdgfra) aggravated susceptibility to the beta cell toxin streptozotocin [7] . These results implicate PDGF receptors as potential targets for additional treatment regimens for diabetes. This could involve the administration of PDGF ligands and/or increased expression of PDGF receptors in beta cells.
Our understanding of the involvement of c-Kit in beta cell function has a more recent history. Expression of c-Kit was detected in embryonic pancreatic epithelial cells or adult islets, and the addition of the c-Kit ligand, stem cell factor SCF, to a culture of fetal islet-like structures increased their insulin content [6, [8] [9] [10] [11] . Expression of c-Kit has been detected on both endocrine and non-endocrine epithelial cells. In addition, SCF or a c-Kit-activating antibody increased the proportion insulin-positive cells in human fetal clusters of epithelial cells that resemble islets [12, 13] . Besides playing a role in beta cell development, c-Kit is also important for adult beta cell function. Male mice harbouring a c-Kit mutation have elevated blood glucose levels and impaired glucose tolerance [14] . They exhibit a reduced beta cell mass and insulin gene expression. Female mutant mice showed a less dramatic phenotype. Surprisingly, the addition of the glycogen synthase kinase 3β (GSK3β) inhibitor 1-azakenpaullone reversed the deleterious effect of the c-Kit mutant on glucose homeostasis, suggesting that the GSK3β pathway is responsible for the adverse effects [15] .
The present investigation shows that elevated expression of c-Kit improves beta cell function, particularly in male mice [3] . The authors adopted a transgenic overexpression strategy allowing the rat insulin promoter to drive beta cell c-Kit expression. As expected, isolated islets exhibited c-Kit overexpression at the RNA and protein level. The mice had improved glucose tolerance, glucose-stimulated insulin secretion and islet insulin content, without showing differences in peripheral insulin sensitivity. The effects were partly due to an increased beta cell mass. Surprisingly, there was an increased mRNA content of various genes related to specific beta cell functions, such as Pdx1, Neurod1, Mafa, Pax6, Nkx2-2, Glut2 and Ins1 and Ins2. The levels of Gcg (encoding glucagon) and the Glp1r mRNA were also increased. Together, the findings point to changes in the beta cell phenotype that yield an improved insulin secretory capacity. The transgenic mice exhibited altered signalling characteristics, with elevated activity of Akt and increased levels of the cell cycle protein cyclin D1. The most important effects were observed when wild-type or c-Kit transgenic mice were placed on a high-fat diet. The transgenic mice were resistant to high-fat-diet-induced impaired glucose tolerance, gained less weight and had lower fasting blood glucose levels and increased glucose-stimulated insulin release. They also exhibited an increased beta cell mass and elevated gene expression of Pdx1, Mafa, Ins1/Ins2, Insr and Irs1. Finally, the transgene partly reversed the deleterious phenotype of the c-Kit mutant with respect to glucose metabolism, clearly implicating c-Kit in the observed beneficial effects.
The increased beta cell mass is not surprising considering c-Kit stimulates cell replication in many systems. What is more puzzling is that the islets perform better, showing an increased secretory capacity and elevated expression of genes associated with the insulin secretory pathway. Is an increased beta cell mass a viable explanation for the secretory changes, allowing the cells to develop a more robust Increased expression and activity of these signalling components will cause further activation of Akt. In addition, increased expression of genes promoting glucose-stimulated insulin secretion, e.g. Pdx1, Mafa, Glut2 and Ins1/Ins2, and those increasing the beta cell mass (Ccnd1 encoding cyclin D1) are observed under these conditions. IR, insulin receptor; PI3K, phosphoinositide 3-kinase secretory phenotype over time, owing to less exposure to possible beta cell challenge or 'exhaustion'? There are other examples of transgenic models with an increased beta cell mass that exhibit an increased insulin secretory capacity [16, 17] . Conversely, there are examples of experimental models with an increased beta cell mass that do not show an increased insulin secretory capacity in response to glucose in vitro [18] , leaving this issue unresolved. It seems plausible that certain changes occurring in the beta cell signal transduction signature promote both cell replication and secretory changes, whereas others stimulate only one of these functional aspects.
Increased Akt activity was noted [3] , and this is an anticipated finding since SCF-stimulated c-Kit is known to activate Akt [1] . On the other hand, increased expression of the insulin receptor and IRS1 was also detected and, if these changes are translated into augmented signalling, they would also result in stimulated Akt (Fig. 1) . One potential target downstream of Akt is forkhead box protein O1 (FOXO1), but this transcription factor was presently not investigated. Another target of Akt is GSK3β which becomes phosphorylated at an inhibitory site (Fig. 1) . The importance of GSK3β in the present context is inferred from the finding that selective beta cell-specific ablation of the gene encoding GSK3β increases the beta cell mass, the insulin secretory response and resistance to the deleterious effects of a high-fat diet [19] . In addition, GSK3β was also found to regulate the expression of IRS1 and IRS2, providing another piece of the puzzle of which interactions are of relevance to the present study. As mentioned above, inhibition of the kinase by 1-azakenpaullone reversed the detrimental effects of the c-Kit mutation and GSK3β appears to be the common denominator for regulation of the beta cell mass and insulin secretion. Surprisingly, beta cell-specific Akt overexpression did not improve glucose stimulated insulin secretion [18] , suggesting that other pathways besides Akt may be required for the complete phenotype. Interestingly, GSK3β activity potentially provides a mechanistic link to the type 2 diabetes susceptibility gene TCF7L2 [20] , since GSK3β regulates the levels of β-catenin, a factor that forms a transcriptionally active complex with transcription factor 7-like 2 (TCF7L2) upon entry to the nucleus.
Using a rat insulin promoter to drive transgene expression will certainly overexpress the target gene in beta cells, but expression at other sites, including the hypothalamus, must be considered. There is currently no indication of possible off-target expression of the transgene (whole brain expression of the transgene could not be detected), but this must not be disregarded as a possibility with respect to some metabolic effects. The failure of the transgenic mice to increase in weight on exposure to a high-fat diet is one such instance. Does targeted beta cell expression of c-Kit present any potential adverse effects? A rapid drop in blood glucose was observed in response to food deprivation, and this could present a problem in conditions of scant food supply. The potential danger of an unbalanced beta cell mass was recently discussed [21] in the context of tissue-specific repression of Pdgfra, as well as other growth-stimulating genes [22] . Perhaps restrained c-Kit expression in beta cells is a mechanism of protection against episodes of hypoglycaemia between meals owing to excess insulin.
Ideally, targeted beta cell-specific gene transfer of c-Kit seems an attractive strategy for treating imbalances in glucose homeostasis. However the technology as it stands at present does not allow such manipulation and therefore alternative strategies must be considered. The presently available option is using a molecular inhibitor of GSK3β such as 1-azakenpaullone to achieve ameliorating effects but this is an unsatisfactory strategy, since GSK3β has multiple roles in diverse organs. Further delineation of the precise signalling cascade converging at GSK3β may help to identify a key component(s) more specific for the beta cell that could serve as a druggable target for the treatment of type 2 diabetes. However, species differences between humans and rodents should also be taken into account, since human beta cells show a much lower capacity for replication in adulthood [23] than rodent cells; thus, the anticipated effect of cKit may, in such a case, become insignificant. On the other hand, if the insulinotropic effect prevails despite modest or undetectable beta cell replication in human beta cells, c-Kit activation may still be considered a relevant strategy for developing novel treatment regimens.
